Blood Pressure: for the advancement of hypertension research

Journal

Publication Venue For

  • Thirty years with LIFE—a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy.  31:125-128. 2022
  • In memoriam: Jiří Widimský Sr. 1925-2020..  30:140-142. 2021
  • Better drug adherence improves blood pressure control and lowers cardiovascular disease outcomes–from single pill combinations to monitoring of a nationwide health insurance database.  30:143-144. 2021
  • Blood pressure target in patients with hypertension and type-2 diabetes older than 65 years. Is <130/80 mmHg the right target or an excessive objective preventing from achieving the clinical goals we are aiming at?.  30:79-81. 2021
  • Combining proteomics, home blood pressure telemonitoring and patient empowerment to improve cardiovascular and renal protection.  30:267-268. 2021
  • Cuff-less measurements of blood pressure: are we ready for a change?.  30:205-207. 2021
  • Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers.  30:1-3. 2021
  • The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug.  30:327-331. 2021
  • In memoriam: Peter Sleight 1929-2020..  29:382-384. 2020
  • The International Society of Hypertension Guidelines 2020–a new drug treatment recommendation in the wrong direction?.  29:264-266. 2020
  • Intensive systolic blood pressure control and prevention of new onset atrial fibrillation in the SPRINT study: is the association really controversial?.  29:199-201. 2020
  • Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project.  29:135-136. 2020
  • How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers.  29:68-69. 2020
  • Over-the-counter mouthwash use, nitric oxide and hypertension risk.  29:103-112. 2020
  • The Health Outcomes Prevention and Evaluation 4 (HOPE 4) project: A successful community-based intervention to lower cardiovascular risk in people with hypertension.  29:1-2. 2020
  • Was it optimal to drop a diuretic as a first-line choice of drug treatment in the 2020 International Society of Hypertension Guidelines?.  29:341-343. 2020
  • Systolic blood pressure control prevents cognitive decline and slows development of white matter lesions in the brain: the SPRINT MIND study outcomes.  28:356-357. 2019
  • The PARAGON-Heart failure trial–another disappointment for heart failure patients with hypertension and preserved ejection fraction.  28:276-278. 2019
  • The PARAGON Heart Failure trial–ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction.  28:215-216. 2019
  • Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited.  28:144-145. 2019
  • Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?.  28:75-76. 2019
  • New data on antihypertensive drugs and risk of cancer: should we worry?.  28:1-3. 2019
  • 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension.  27:313. 2018
  • Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study.  27:247-248. 2018
  • Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure.  27:185-187. 2018
  • In memoriam: Alberto Zanchetti..  27:123-124. 2018
  • New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?.  27:62-65. 2018
  • Challenges in oscillometric blood pressure measurement in atrial fibrillation: looking for practical solutions.  27:1-2. 2018
  • Renal denervation in hypertension: is it the end or the beginning of a SPYRAL?.  26:319-320. 2017
  • Treatment strategies for comorbid conditions lower residual risk in patients with treated hypertension: FOURIER and other randomized outcome trials.  26:257-258. 2017
  • The INTERSTROKE Study: hypertension is by far the most important modifiable risk factor for stroke.  26:131-132. 2017
  • The INTERSALT Study and the complex relationship between salt intake and blood pressure.  26:65-66. 2017
  • The Global Burden of Disease Study 2015 and Blood Pressure.  26:1. 2017
  • Blood Pressure in 2016: increased impact factor and change of editors.  25:331-332. 2016
  • The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease.  25:276-279. 2016
  • The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg.  25:1-3. 2016
  • Hypertension Management by Practice Guidelines.  23:1-2. 2014
  • Renal denervation in treatment-resistant hypertension-Oslo RDN, Symplicity HTN-3 and INSPiRED randomized trials.  23:135-137. 2014
  • Revisiting the pre-hypertension debate: Increasing evidence for treatment-or not.  22:344. 2013
  • Blood pressure lowering effect of renal sympathetic denervation or placebo? - Building expectations for Symplicity-HTN 3.  22:279-281. 2013
  • 2013 European society of hypertension/European society of cardiology hypertension guidelines.  22:191-192. 2013
  • Primary cardiovascular prevention by Mediterranean diet - The PREDIMED trial.  22:129-130. 2013
  • Angiotensin receptor - Neprilysin inhibiton (ARNI) A novel therapeutic concept for management of hypertension and heart failure.  21:329-330. 2012
  • Direct renin inhibitors in hypertension Approaching the moment of truth.  21:267-268. 2012
  • Increased time varying heart rate and cardiovascular risk in hypertension Benefit of selective I (f) channel inhibitor?.  21:1-2. 2012
  • An appropriate SCORE to assess cardiovascular risk in hypertension?.  20:320-321. 2011
  • Renal nerve ablation: Emerging role in therapeutics.  20:253-255. 2011
  • High mortality explained by mildly elevated blood pressure in Scandinavian adolescent conscripts A plea for early drug treatment?.  20:188-189. 2011
  • Treatment of high blood pressure in acute stroke - The SCAST Study.  20:67-68. 2011
  • Antihypertensive therapy and cancer risks?.  20:127-128. 2011
  • Cardiovascular risks in HIV patients.  19:325-327. 2010
  • Editorial: Blood pressure and migration.  19:65-66. 2010
  • Editorial: Hypertension research into the new millennium.  19:1-2. 2010
  • Angiotensin receptor blockers and cancer - Relationship dismissed by VALUE data while waiting for EMA and FDA reports.  19:271-272. 2010
  • Editorial: Blood Pressure celebrates 20 years of dedication to Nordic hypertension research.  19:130-131. 2010
  • Editorial: Blood pressure variability: Emerging role in risk assessment and therapeutics.  19:209-211. 2010
  • Does GISSI-AF change the concept of using RAS inhibitors in the primary prevention of atrial fibrillation in hypertensive patients?.  18:92-93. 2009
  • The J-curve phenomenon revisited.  18:168-170. 2009
  • Editorial: Critical aspects in hypertension diagnosis and treatment.  18:3-4. 2009
  • Editorial: Should we treat prehypertension?.  18:298-299. 2009
  • Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: The Losartan Intervention for Endpoint reduction in hypertension study.  18:348-361. 2009
  • ONTARGET, TRANSCEND and PROFESS - Clarifying, confusing or misleading?.  18:4-6. 2009
  • Critical aspects in hypertension diagnosis and treatment.  18:3-4. 2009
  • Benefits of hypertension management in diabetes: An opportunity not to be missed.  17:248-249. 2008
  • Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective.  17:260-269. 2008
  • More focus on therapeutic targets and improved tolerability in hypertension.  17:3-4. 2008
  • Management of older hypertensive patients.  17:184-185. 2008
  • More is less? Optimal combination therapy for adequate blood pressure lowering in hypertension.  17:132-133. 2008
  • A stunning day in hypertension research - Results of ONTARGET, ACCOMPLISH and HYVET.  17:68-69. 2008
  • Urgent need to address quality control issues of out-of-office blood pressure measurement and patient risk assessment.  17:5-6. 2008
  • Achieving better blood pressure control.  17:3-4. 2008
  • Ambulatory blood pressure adds to explaining benefits of AT-1 receptor blockade in the treatment of left ventricular hypertrophy.  16:344-346. 2007
  • Hypertension and cardiovascular disease: Is arterial stiffness the heart of the matter.  16:236-237. 2007
  • New ESH/ESC Guidelines signal progress in hypertension management.  16:132-134. 2007
  • Blood pressure control - Slowly getting there through new strategies?.  16:68-71. 2007
  • Documentation of endpoint prevention with combination therapy in hypertension is urgently needed.  16:4-5. 2007
  • Beta-blockers as sub-optimal treatment for hypertension: Time for first-line therapy revision?.  15:323-324. 2006
  • The question of whether diabetes and its cardiovascular risks can be prevented: A realistic DREAM?.  15:260-262. 2006
  • Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: The LIFE study.  13:376-384. 2004
  • Essential hypertension in women.  13:272-278. 2004
  • International Standard Serial Number (issn)

  • 0803-7051
  • Electronic International Standard Serial Number (eissn)

  • 1651-1999